JCJonathan P. Callaghan

Jonathan P. Callaghan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jonathan P. Callaghan has a total of 19 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Tumour–Stroma Ratio as a Predictive Biomarker for Neoadjuvant Therapy Efficacy in Rectal Cancer

    by Jonathan P. Callaghan, Caroline R. Cartlidge, Kenal Patel, Nicholas P. West

    Background: The treatment of rectal cancer frequently involves a multimodal approach, including neoadjuvant therapy prior to surgery in patients with locally advanced disease. However, the response to such treatment is variable. Robust biomarkers to predict neoadjuvant therapy response represent an unmet clinical need; they could help to stratify patients for organ preservation strategies or treatment intensification. The tumour–stroma ratio (TSR) is an established prognostic marker that has recently gained attention for its potential predictive value when assessed in pre-treatment biopsies. Objective: This narrative review critically evaluates the existing evidence regarding TSR as a predictive biomarker for neoadjuvant therapy response in rectal cancer. Results: Emerging evidence from retrospective studies of large cohorts suggests that stroma-high tumours often demonstrate resistance to standard neoadjuvant chemoradiotherapy, resulting in lower major pathological response rates. Conversely, some smaller studies report no significant association between biopsy TSR and treatment efficacy. This conflicting evidence could be attributable to methodological heterogeneity, including inconsistent definitions, varying measurement techniques (manual versus automated), and mixed patient cohorts. The predictive value of TSR appears to be neoadjuvant regimen-specific, with stroma-high phenotypes interacting differently with treatments like short-course radiotherapy or intensified chemotherapy. Conclusions: TSR is a simple, biologically plausible, and readily assessable promising biomarker with apparently predictive as well as prognostic potential. It is likely to represent a regimen-specific predictor rather than a universal marker of resistance to neoadjuvant therapy in rectal cancer. Future clinical translation will require standardised, AI-driven quantification and robust prospective clinical validation.

  • Open Access

    Tumour-Infiltrating Lymphocytes, Tumour Cell Density, and Response to Neoadjuvant Short-Course Radiotherapy in Rectal Cancer: A Translational Sub-Study from the MRC CR07 Clinical Trial

    by Jonathan P. Callaghan, Ross Jarrett, Alice C. Westwood, Jon Laye, Philip Quirke, Derek R. Magee, Daniel Bottomley, David Sebag-Montefiore, Lindsay Thompson, Angela Meade, et al.

    Background: Rectal cancer is common and frequently treated with neoadjuvant radiotherapy prior to surgery to reduce the risk of tumour recurrence. However, the therapeutic benefits and side effects of radiotherapy can vary between patients, and there are currently no validated biomarkers to predict treatment response. Tumour cell density (TCD) and tumour-infiltrating lymphocyte (TIL) density are proven prognostic biomarkers in colorectal cancer; however, their utility in predicting radiotherapy response remains unclear. We assessed the prognostic and predictive value of TCD and TIL density in rectal cancer patients treated with radiotherapy. Methods: TCD was quantified using a manual point-counting method in 253 pre-treatment biopsies and across the entire tumour area of 569 resection specimens from the MRC CR07 clinical trial, which randomised patients to either neoadjuvant short-course radiotherapy (SCRT) or straight to surgery (control). TIL density was measured in 102 biopsies and matched resection specimens (73 SCRT, 29 control) across different tumour areas using deep learning-based cell detection in MIM (HeteroGenius Ltd., Leeds, UK). Cutoffs for low/high-TCD and TIL density were both pre-defined and derived from survival data using the survminer R package. Survival analyses were performed to evaluate the predictive and prognostic value of TCD/TIL in relation to overall and cancer-specific survival. Results: TCD in the resection specimens was lower in the SCRT group (19.9%, IQR 12.9–26.7%) than the control group (34.3%, IQR 27.7–40.5%, p < 0.001). In control resections, low-TCD was associated with a higher risk of all-cause mortality (HR 2.20, 95% CI 1.41–3.44, p < 0.001) and cancer-related death (HR 2.69, 95% CI 1.41–5.13, p = 0.0026). In contrast, after SCRT, low resection TCD was associated with a reduced risk of death (HR 0.63, 95% CI 0.40–0.98, p = 0.04). In the SCRT group, low biopsy TCD prior to radiotherapy was associated with a reduced risk of cancer-related death (HR 0.34, 95% CI 0.13–0.89, p = 0.028). Across both trial arms, TIL density was higher in pre-treatment biopsies than resections (2492 vs. 1304/mm2, p < 0.001). Low biopsy TIL density was associated with an increased risk of all-cause mortality (HR 2.43, 95% CI 1.24–4.76, p = 0.01). The SCRT group had lower TIL density in the resection compared with controls (1210 vs. 1615/mm2, p < 0.001), and low resection TIL density across the whole tumour area was associated with a higher risk of death (HR 2.55, 95% CI 1.11–5.87, p = 0.027). Conclusions: Our findings support the role of TCD and TIL density as quantitative biomarkers in rectal cancer patients. TCD can be used to assess the degree of response to radiotherapy, and contrasting survival associations are observed between straight-to-surgery and SCRT-treated patients. This study raises the possibility of using TCD as both a prognostic and predictive biomarker. TIL density failed to show predictive value but demonstrated expected prognostic associations.


  • Open Access

    Entropy and expertise: assessing changes in pathologists' language over time using the UK Liver Pathology External Quality Assessment scheme

    by Jonathan P Callaghan, Katrina Z Freimane, Rachel M Brown, Alyn L Cratchley, Timothy J Kendall

    External Quality Assessment (EQA) schemes are an important quality assurance tool and aim to ensure consistency among histopathologists. In this study, we use Shannon entropy as a novel metric to evaluate linguistic variability in the UK Liver Pathology EQA scheme. Analysing free‐text responses by participants over a decade, we aimed to quantify language trends in morphological assessments and clinicopathological diagnoses. Accounting for an increasing word count and when pathologists joined the scheme, our findings reveal a significant increase in entropy of morphological assessments over time, indicating growing linguistic diversity that may reflect the increasing complexity of liver pathology. Entropy of clinicopathological diagnoses over the same period did not provide clear evidence for convergent diagnostic language. High entropy corresponded to cases that elicited more diverse responses and could be considered more challenging, highlighting the utility of this method to identify potential areas for targeted education. We demonstrate entropy as a novel tool to analyse pathologist language and enhance quality assurance in the evolving pathology landscape.

  • Open Access

    (L)earning: Exploring the value of paid roles for medical students

    by Jonathan P. Callaghan, Katrina Z. Freimane, Grainne P. Kearney, Nigel D. Hart

    Background: The Medical Student Technician (MST) role is a paid position established in Northern Ireland in 2020. The Experience‐Based Learning (ExBL) model is a contemporary medical education pedagogy advocating supported participation to develop capabilities important for doctors‐to‐be. In this study, we used the ExBL model to explore the experiences of MSTs and how the role contributed to students' professional development and preparedness for practice. Methods: A convenience sampling strategy was used to recruit a total of 17 MSTs in three focus groups. Semi‐structured interviews were transcribed verbatim and analysed using the ExBL model as a framework. Transcripts were independently analysed and coded by two investigators and discrepancies resolved with the remaining investigators. Results: The MST experiences reflected the various components of the ExBL model. Students valued earning a salary; however, what students earned transcended the financial reward alone. This professional role enabled students to meaningfully contribute to patient care and have authentic interactions with patients and staff. This fostered a sense of feeling valued and increased self‐efficacy amongst MSTs, helping them acquire various practical, intellectual and affective capabilities and subsequently demonstrate an increased confidence in their identities as future doctors. Conclusion: Paid clinical roles for medical students could present useful adjuncts to traditional clinical placements, benefiting both students and potentially healthcare systems. The practice‐based learning experiences described appear to be underpinned by a novel social context where students can add value, be and feel valued and gain valuable capabilities that better prepare them for starting work as a doctor.